



Human Anti-Human VEGF (Aflibercept) Monoclonal Antibody, clone Aflibercept [Biosimilar] (CABT-Z819H)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Specificity	Detects human VEGF. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Aflibercept.
Immunogen	Human VEGF.
Isotype	IgG1
Source/Host	Human
Species Reactivity	Human
Clone	Aflibercept
Purification	Protein A or G purified
Conjugate	Functional Grade
Applications	FA
Format	Liquid
Concentration	Lot specific
Size	1 mg
Buffer	0.01 M phosphate buffered saline (PBS) pH 7.2, 150 mM NaCl with no carrier protein, potassium or preservatives added. BSA and Azide free. Endotoxin Level \leq 0.75 EU/mg as determined by the LAL method

Preservative	None
Storage	Store at 2-8°C for short term; -80°C for long term. Avoid freeze / thaw cycle.
Ship	Wet ice

BACKGROUND

Introduction	Aflibercept biosimilar is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration. Aflibercept biosimilar is a dimeric glycoprotein with a protein molecular weight of 97 kilodaltons (kDa) and contains glycosylation, constituting an additional 15% of the total molecular mass, resulting in a total molecular weight of 115 kDa. Aflibercept biosimilar is produced in recombinant Chinese hamster ovary (CHO) cells.
Keywords	VEGF;vascular endothelial growth factor ;vascular endothelial growth factor , VEGF;vascular permeability factor